The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes.
Retrospective and uncontrolled studies suggest that the lipid-lowering statin class of drugs has either no or beneficial effects on bone density and may reduce fracture risk. We have examined the effects of atorvastatin on serum and plasma markers of bone turnover in 25 patients (age 56 +/- 8 years) with type 2 diabetes (duration: 4.7 +/- 5.0 years, 16 female, 2 insulin-treated, 4 diet alone, and 19 on oral hypoglycemic agents) and baseline hypercholesterolemia (cholesterol 6.6 +/- 0.8 mmol/l) in a double-blind, placebo-controlled, crossover study of 12 weeks of placebo/40 mg of atorvastatin with an 8-week wash-out period. Atorvastatin resulted in a fall in total cholesterol of 2.3 +/- 0.9 mmol/l. There were no effects of active or placebo therapy on total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, or beta C-telopeptide of type 1 collagen (beta-CTX). We conclude that atorvastatin (40 mg/day) has no significant effect on bone turnover in man.
Braatvedt
G D
GD
University Department of Medicine, Auckland Hospital, University of Auckland, Auckland, New Zealand. g.braatvedt@auckland.ac.nz
Bagg
W
W
Gamble
G
G
Davidson
J
J
Reid
I R
IR
D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D016001:Confidence Intervals; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use*
D015415:Biomarkers; D006538:Heptanoic Acids; D011758:Pyrroles; D015675:Osteocalcin; D000069059:Atorvastatin